Currently, noni schemic dilated cardiomyopathy (NICM) represents the leading cause of advanced heart failure, accounting for >50% of all heart transplantation procedures. We propose that when compared with patients with ischemic heart failure (IHF), patients with NICM demonstrate a more favorable clinical response to cell therapy, which offers a potential novel promising treatment approach for this patient population. Chronic heart failure represents one of the most important healthcare problems worldwide. Although survival after diagnosis of heart failure has improved, overall mortality remains high.1 In the recent years, several novel approaches for heart failure management have been tested in clinical trials, with cell therapy representing one of potentially more promising treatment modalities. The majority of clinical trials of cell therapy in chronic heart failure have been focusing on patients with IHF. In this cohort, early trials demonstrated clinical benefits and an improvement in left ventricular function after cell therapy; however, subsequent larger trials failed to confirm these findings. Furthermore, a recent meta-analysis of 38 randomized controlled trials in IHF found only low-quality evidence that treatment with bone marrow-derived cells reduces mortality and improves left ventricular ejection fraction (LVEF).2 Although the reasons for the inconsistent results remain poorly defined, they could be partially explained by the fact that despite the potential beneficial effects on the myocardium, cell therapy does not affect the progression of atherosclerosis, which may limit the clinical efficacy of this approach in patients with IHF. In the last decade, NICM has become the leading cause of advanced heart failure, accounting for >50% of all heart transplantations.1 These trends indicate that patients with NICM may represent the largest subpopulation of heart failure patients with a particular need for alternative treatment modalities, including cell therapy. The disease progression …

中文翻译：

---

非缺血性心肌病的细胞疗法

目前，诺丽菌性缺血性心肌病（NICM）代表晚期心力衰竭的主要原因，占所有心脏移植手术的50％以上。我们建议，与缺血性心力衰竭（IHF）患者相比，NICM患者表现出对细胞疗法更有利的临床反应，这为该患者群体提供了一种潜在的新颖有希望的治疗方法。慢性心力衰竭是全球最重要的医疗保健问题之一。尽管心力衰竭诊断后的生存率得到了改善，但总体死亡率仍然很高。1近年来，临床试验中已测试了几种用于心力衰竭管理的新方法，其中细胞疗法代表了一种潜在的更有前景的治疗方式。慢性心力衰竭的细胞疗法的大多数临床试验都集中在IHF患者上。在这个队列中，早期试验证明了细胞治疗后的临床益处和左心室功能的改善；但是，随后的较大试验未能证实这些发现。此外，最近对IHF中38项随机对照试验的荟萃分析发现，只有低质量的证据表明，用骨髓源性细胞治疗可降低死亡率并改善左心室射血分数（LVEF）。2尽管结果不一致的原因仍然很差定义是，尽管对心肌有潜在的有益作用，但细胞疗法不会影响动脉粥样硬化的进展，因此可以部分解释这些问题。这可能会限制这种方法在IHF患者中的临床疗效。在过去的十年中，NICM成为晚期心力衰竭的主要原因，占所有心脏移植的50％以上。1这些趋势表明，NICM患者可能是心力衰竭患者的最大亚群，特别需要替代疗法形式，包括细胞疗法。疾病进展……